Business & Finance

Bradmer Pharmaceuticals reports loss of $0.059 per share

Published in Healthcare Finance, Tax and Law Weekly, January 31st, 2007

Bradmer Pharmaceuticals, Inc., a clinical oncology company specializing in the development and commercialization cancer therapies, announced its 2006 third quarter operational and financial results.

During the 3-month period ended September 30, 2006, the company achieved the following steps in preparation for the upcoming multicenter trial for Neuradiab and its subsequent planned commercialization:

1) Recruited Alan M. Ezrin, PhD, to join the company as chief operating officer.

2) Submitted a request to the U.S. Food and Drug Administration (FDA) for an end of phase II meeting on Neuradiab.

3) Submitted an E.U....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry